Shanghai United Imaging Healthcare Co (688271) Fair Value & Analysis
Healthcare · CN · Market cap 92.3B CNY
Fair value as of: Aug 13, 2026
From 26 valuation models · updated yesterday
Share price −0.4% over the past month.
A solid business, but screening 60% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥54.53). The favourable scenario is already priced in.
- Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥29.58 to ¥54.53) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
48‑month range ¥92.44 – ¥213.20 · fair‑value band ¥29.58 – ¥54.53 · the ¥108.40 price screens above the ¥43.60 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Shanghai United Imaging Healthcare Co (688271) currently trades at ¥108.40, while our model-based Fair Value estimate is ¥43.60, implying the stock looks roughly 59.8% overvalued today. The Quality Score stands at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shanghai United Imaging Healthcare Co generated revenue of 14.2B CNY at a net margin of 13.3%. Revenue grew 17.3% year over year. It earns a return on equity of 8.9%. Net debt stands at 109M CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥29.58 (bear case) to ¥54.53 (bull case); at ¥108.40, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 34% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -60%, 688271 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥64.82) versus Dividend Discount (¥3.44). Highest evidence: Growth DCF (80).
Notify me when 688271 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai United Imaging Healthcare Co., Ltd. engages in the provision, development, and production of advanced medical imaging solutions, radiotherapy equipment, life science instruments, and intelligent digital solutions worldwide. The company provides molecular imaging products; and magnetic resonance imaging solutions.
Full company description
Shanghai United Imaging Healthcare Co., Ltd. engages in the provision, development, and production of advanced medical imaging solutions, radiotherapy equipment, life science instruments, and intelligent digital solutions worldwide. The company provides molecular imaging products; and magnetic resonance imaging solutions. It also offers computed tomography equipment; digital radiography equipment; mammography equipment; angiography equipment; mobile C-arm equipment; and radiotherapy systems comprising uRT-linac 506c, uRT-linac 306, and Intelligent RT Cloud Ecosystem. In addition, it provides uVision, a remote vision system that enables real-time positioning observation and automatic field of view identification; a low-dose, 3D mammography platform; and Remote Vision and Exposure Control technology application, a handheld X-ray from UIH that enables accurate positioning while reducing exposure radiation. Further, the company offers United Neuro, a medical imaging software used to analyze functional magnetic resonance imaging and diffusion tensor imaging data, and U-VIEWER, software that helps in viewing DICOM images. Additionally, it provides training, monitoring, maintenance, and troubleshooting services. Shanghai United Imaging Healthcare Co., Ltd. was founded in 2011 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai United Imaging Healthcare Co reported revenue of ¥13.8B in FY2025 versus ¥7.3B in FY2021, a compound +17.4%/yr. Reported net income was ¥1.9B in FY2025, compounding +7.2%/yr from FY2021.
688271 screens 60% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 345 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
| CLASSYS Inc 214150 | 39,700 KRW | 20,415 KRW | -49% |
Compare Shanghai United Imaging Healthcare Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai United Imaging Healthcare Co (688271) overvalued or undervalued?
What is the fair value of 688271?
What is the quality score of 688271?
What is the revenue of Shanghai United Imaging Healthcare Co (688271)?
What is the net profit margin of 688271?
Does Shanghai United Imaging Healthcare Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai United Imaging Healthcare Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.